Dr. Kenneth J. Warrington, MD

Dr. Warrington practices at Mayo Clinic Hospital, Saint Marys Campus in Rochester, Minnesota, part of Mayo Clinic.

Dr. Warrington's NPI, 1184682916, was assigned on May 2, 2006. Dr. Warrington holds Minnesota license 41113.

Dr. Warrington's primary practice is Mayo Clinic Hospital, Saint Marys Campus, at 1216 Second Street Southwest, Rochester, MN 55902 in Olmsted County. The practice phone is (507) 255-5123.

Dr. Warrington's primary practice is Mayo Clinic Hospital, Saint Marys Campus in Rochester, Minnesota, part of Mayo Clinic. Dr. Warrington is also affiliated with Mayo Clinic Health System in Mankato. The medical group on file is Mayo Clinic. Dmand AI also links Dr. Warrington to 2 more hospitals and 1 hospice, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Warrington practices, 5 sites in all. Vendor and product names are available with a free account.

Rheumatology is Dr. Warrington's primary specialty in the NPI Registry, under taxonomy code 207RR0500X. Dmand AI has Dr. Warrington's licenses on file in 2 states: Minnesota and Tennessee.

CMS data shows 3,765 Medicare services from Dr. Warrington across 9 procedure codes in 2024, for 224 Medicare patients. Medicare paid $26,545 for them. Every service was in an office.

CMS counts 224 Medicare patients who saw Dr. Warrington in 2024. The largest group is 65 to 74, with 105 patients. 74% of them have high blood pressure, and 69% have high cholesterol. 8% are also on Medicaid. Their average risk score is 1.56, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Warrington's median patient age at 68, with 63% women.

In 2024, Dr. Warrington wrote 285 Medicare Part D claims for 75 patients. 83% of them were for generic drugs. CMS names the drug for 242 of them, across 6 drugs with 11 or more claims each, at $386,654 in total drug cost. In 2023, CMS named 276 claims across 8 drugs.

Dr. Warrington accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Warrington as offering telehealth.

Dmand AI links 176 papers to Dr. Warrington, published from 2017 to 2025. 2022 was the busiest year, with 25. The most frequent topics are Giant Cell Arteritis, Glucocorticoids and Takayasu Arteritis. Dr. Warrington has published most often in Rheumatology (Oxford). Dr. Warrington's most frequent co-authors are Tanaz A. Kermani, MD, Carol A. Langford, MD and Paul A. Monach, MD, PhD.

Dmand AI links Dr. Warrington to 3 clinical trials. Conditions studied include Giant Cell Arteritis, Vasculitis, Central Nervous System and Polymyalgia Rheumatica. Sanofi sponsors the most, 2. Open Payments lists research payments to Dr. Warrington that name 3 trials.

CMS Open Payments shows 26 general payments to Dr. Warrington from 4 drug and device companies from 2017 to 2025. Consulting fees make up the largest share, 58% of the total. Sanofi and Genzyme US Companies paid the most, $22,715. It also lists 7 research payments totaling $14,983 from 2016 to 2021, naming 3 clinical trials.